Indacaterol

BreastfeedingPediatric
  • TRADE NAMES: Arcapta Neohaler (Novartis); Onbrez Breezhaler (Novartis); Utibron Neohaler (Novartis)
  • INDICATIONS: Long term, once-daily maintenance bronchodilator treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
  • CLASS: Beta-2 adrenergic agonist, Bronchodilator
  • HALF-LIFE: 40–56 hours

FDA APPROVAL DATE: 07/01/2011

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acetazolamide, Adrenergics, Aminophylline, Arsenic, Corticosteroids, Diuretics, Erythromycin, Ketoconazole, MAO inhibitors, Pazopanib, QT prolonging agents, Ritonavir, Steroids, Telavancin, Theophylline, Tricyclic antidepressants, Verapamil, Xanthine derivatives

PREGNANCY CATEGORY: C

Studies in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death.

Contra-indicated in patients with asthma without use of a long-term asthma control medication.

Utibron Neohaler is indacaterol and glycopyrrolate.

ASTHMA-RELATED DEATH

See full prescribing information for complete boxed warning.

Our database has 36 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Indacaterol in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top